.svg){kind=small}
Oct-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Is this your brand?
See your full sales and distribution data: where you sell, how you're priced, and how you rank against the brands next to you on the shelf.
See your brand's dataCarry this brand in your store?
Headset Retailer is free. Connect your POS and see what's selling and what's sitting.
Sign up freeWhere to Buy
Avexia is stocked at 502 licensed dispensaries across Illinois, New Jersey, and 8 other states, 137 of them in Illinois, with the deepest coverage in Chicago, Springfield, Quincy, Champaign, and Naperville. Search by ZIP code or city below to find the closest one, or filter by product type if you are after a specific format.
Market Insights Snapshot
Avexia concentrated half of its October 2026 volume in Topical at 50.60% share while Capsules held 27.76%, marking a category tilt even as brand sales declined 29.53% year over year and 63.80% over 24 months. Within the mix, Topical grew 24.05% month over month but fell 15.63% year over year, Capsules slipped 3.28% MoM yet inched up 0.40% YoY, and Concentrates contracted 14.61% MoM and 57.50% YoY. Tincture & Sublingual dropped 53.70% MoM and 70.48% YoY, compressing to 3.26% share. Despite a 10.47% YoY decline in average price to $27.01, Avexia’s Topical rank hit 1 in Illinois, implying the brand is leaning into a defensible Topical position while de-emphasizing long‑tail formats with steep YoY erosion.
The mix shift toward Topical (+24.05% MoM vs. Capsules −3.28% MoM) alongside a category where Avexia holds rank 1 in Illinois signals an intentional pivot to defend share where pricing power can offset a 10.47% average price decline, whereas deep YoY drops in Concentrates (−57.50%) and Tincture & Sublingual (−70.48%) suggest pruning or loss of relevance in formats with higher volatility. With Topical at 50.60% share and Concentrates at 18.38%, the brand is trading breadth for depth; this positioning can stabilize near‑term rank but heightens exposure to a single category cycle if Topical’s −15.63% YoY trend persists.
Competitive Landscape
Avexia is currently ranked #1 in IL Topical in October 2026, unchanged from #1 year over year, with a stable three-month position at #1 and a peak rank of #1 also in October 2026; in the same period, Doctor Solomon's held at #2 while its sales fell 13.2% YoY, and Alchemy (Ieso) climbed from #5 to #4 on 89.3% YoY growth, indicating Avexia’s unchanged #1 rank is being sustained more by competitor stagnation or volatility than by rank-based gains of its own, which implies durability but also rising pressure from faster-movers just below.
Notable Products
Avexia’s October 2026 sales are concentrated, with the top 10 items accounting for 79.4% and the CBD/THC 1:1 Harmony Pain Relief Balm alone at 39.9%, so most of its sales ride on a small set of core products.
Peer avg: average price of the same product type and package size in the same states that month.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
